Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2012119989) ANTIBODIES AGAINST CADMI FOR THE DIAGNOSIS AND TREATMENT OF CANCER
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1 . An antibody that specifically binds to CADM 1 , wherein the variable region of the heavy chain of said antibody comprises a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 79, SEQ ID NO. : 86, SEQ ID NO. 78, SEQ ID NO. : 77 or SEQ ID NO.: 84, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

2. The antibody of claim 1 , wherein the variable region of the heavy chain of said antibody comprises a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 55, SEQ ID NO: 62, SEQ ID NO: 54, SEQ ID NO: 53 or SEQ ID NO:60, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

3. The antibody of claim 1 or 2, wherein the variable region of the heavy chain of said antibody comprises a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 67, SEQ ID NO: 74, SEQ ID NO: 66, SEQ ID NO: 65 or SEQ ID NO:72, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

4. The antibody of any one of claims 1 to 3, wherein the variable region of the heavy chain of said antibody comprises:

(i) a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 55 , a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 67 , and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 79, or a CDR sequence having 75% or more amino acid identity to one of said CDRs;

(ii) a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 62 , a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 74 , and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 86, or a CDR sequence having 75% or more amino acid identity to one of said CDRs;

(iii) a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 54 , a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 66 , and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 78, or a CDR sequence having 75% or more amino acid identity to one of said CDRs;

(iv) a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 53 , a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 65 , and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 77, or a CDR sequence having 75% or more amino acid identity to one of said CDRs; or

(v) a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 60 , a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 72 , and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO. : 84, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

5. The antibody of any one of claims 1 to 4, wherein the variable region of the light chain of said antibody comprises a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 43, SEQ ID NO. : 50, SEQ ID NO. 42, SEQ ID NO. : 41 or SEQ ID NO.: 48, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

6. The antibody of any one of claims 1 to 5, wherein the variable region of the light chain of said antibody comprises a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 19, SEQ ID NO: 26, SEQ ID NO: 18, SEQ ID NO: 17 or SEQ ID NO:24, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

7. The antibody of any one of claims 1 to 6, wherein the variable region of the light chain of said antibody comprises a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 31 , SEQ ID NO: 38, SEQ ID NO: 30, SEQ ID NO: 29 or SEQ ID NO:36, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

8. The antibody of any one of claims 1 to 7, wherein the variable region of the light chain of said antibody comprises:

(i) a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 19 , a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 31 , and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 43, or a CDR sequence having 75% or more amino acid identity to one of said CDRs;

(ii) a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 26 , a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 38 , and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 50, or a CDR sequence having 75% or more amino acid identity to one of said CDRs;

(iii) a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 18 , a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 30 , and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 42, or a CDR sequence having 75% or more amino acid identity to one of said CDRs;

(iv) a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 17 , a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 29 , and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 41 , or a CDR sequence having 75% or more amino acid identity to one of said CDRs; or

(v) a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 24 , a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 36 , and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO. : 48, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

9. The antibody of claim 1 ,

wherein the variable region of the light chain of said antibody comprises a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 19, a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 31 , and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 43, or a CDR sequence having 75% or more amino acid identity to one of said CDRs; and

wherein the variable region of the heavy chain of said antibody comprises a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 55, a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 67, and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO. : 79, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

10. The antibody of claim 1 ,

wherein the variable region of the light chain of said antibody comprises a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 26, a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 38, and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 50, or a CDR sequence having 75% or more amino acid identity to one of said CDRs; and

wherein the variable region of the heavy chain of said antibody comprises a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 62, a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 74, and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 86, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

1 1 . The antibody of claim 1 ,

wherein the variable region of the light chain of said antibody comprises a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 18, a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 30, and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 42, or a CDR sequence having 75% or more amino acid identity to one of said CDRs; and

wherein the variable region of the heavy chain of said antibody comprises a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 54, a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 66, and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 78, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

12. The antibody of claim 1 ,

wherein the variable region of the light chain of said antibody comprises a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 17, a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 29, and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 41 , or a CDR sequence having 75% or more amino acid identity to one of said CDRs; and

wherein the variable region of the heavy chain of said antibody comprises a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 53, a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 65, and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO. : 77, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

1 3. The antibody of claim 1 ,

wherein the variable region of the light chain of said antibody comprises a VL_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 24, a VL_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 36, and a VL_CDR3 region having an amino acid sequence as depicted in SEQ ID NO.: 48, or a CDR sequence having 75% or more amino acid identity to one of said CDRs; and

wherein the variable region of the heavy chain of said antibody comprises a VH_CDR1 region having an amino acid sequence as depicted in SEQ ID NO: 60, a VH_CDR2 region having an amino acid sequence as depicted in SEQ ID NO: 72, and a VH_CDR3 region having an amino acid sequence as depicted in SEQ ID NO. : 84, or a CDR sequence having 75% or more amino acid identity to one of said CDRs.

14. The antibody of any one of claims 1 to 13,

wherein said antibody comprises a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 120, SEQ ID NO:1 12, SEQ ID NO:94, SEQ ID NO: 118 or SEQ ID NO:122, or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to one of said variable VH-regions; or

a variable VH-region having an amino acid sequence as shown in SEQ ID NO:96, SEQ ID NO:111 , SEQ ID NO: 93, SEQ ID NO: 90 or SEQ ID NO:106 , or a variable VH-region having an amino acid sequence which has 75% or more identity to one of said variable VH-regions.

15. The antibody of any one of claims 1 to 14,

wherein said antibody comprises a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 19, SEQ ID NO:1 10, SEQ ID NO: 92, SEQ ID NO: 117 or SEQ ID NO:121 , or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to one of said variable VL-regions; or

a variable VL-region having an amino acid sequence as shown in SEQ ID NO:95, SEQ ID ΝΟ.Ί 09, SEQ ID NO: 91 , SEQ ID NO: 89 or SEQ ID NO 105 , or a variable VL-region having an amino acid sequence which has 75% or more identity to one of said variable VL-regions.

1 6. The antibody of claim 1 , wherein said antibody comprises a variable VH-region and a variable VL-region selected from the group consisting of:

(i) a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 120 or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region, or a variable VH-region having an amino acid sequence as shown in SEQ ID NO:96 or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 1 9 or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VL-region, or a variable VL-region having an amino acid sequence as shown in SEQ ID NO:95 or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region;

(ii) a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 12 or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region, or a variable VH-region having an amino acid sequence as shown in SEQ ID NO:1 11 or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 10 or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VL-region, or a variable VL-region having an amino acid sequence as shown in SEQ ID NO:109 or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region;

(iii) a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO:94 or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region, or a variable VH-region having an amino acid sequence as shown in SEQ ID NO:93 or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO:92 or a variable VL-region as encoded by a nucleic acid

molecule having 75% or more identity to said variable VL-region, or a variable VL-region having an amino acid sequence as shown in SEQ ID NO:91 or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region;

(iv) a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 18 or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region, or a variable VH-region having an amino acid sequence as shown in SEQ ID NO:90 or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 1 7 or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VL-region, or a variable VL-region having an amino acid sequence as shown in SEQ ID NO:89 or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region;

(v) a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 22 or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region, or a variable VH-region having an amino acid sequence as shown in SEQ ID NO: 106 or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 121 or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VL-region, or a variable VL-region having an amino acid sequence as shown in SEQ ID NO:105 or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region.

1 7. The antibody of claim 16,

wherein said antibody comprises a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 120, or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region; or

a variable VH-region having an amino acid sequence as shown in SEQ ID NO:96, or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

wherein said antibody comprises a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 19, or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VL-region; or

a variable VL-region having an amino acid sequence as shown in SEQ ID NO:95, or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region.

18. The antibody of claim 1 6,

wherein said antibody comprises a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 12, or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region; or

a variable VH-region having an amino acid sequence as shown in SEQ ID NO:1 11 , or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

wherein said antibody comprises a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 10, or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VL-region; or

a variable VL-region having an amino acid sequence as shown in SEQ ID NO:109, or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region .

19. The antibody of claim 16,

wherein said antibody comprises a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO:94, or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region; or

a variable VH-region having an amino acid sequence as shown in SEQ ID NO:93, or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

wherein said antibody comprises a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO:92, or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VL-region; or

a variable VL-region having an amino acid sequence as shown in SEQ ID NO:91 , or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region.

20. The antibody of claim 16,

wherein said antibody comprises a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 18, or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region; or

a variable VH-region having an amino acid sequence as shown in SEQ ID NO:90, or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

wherein said antibody comprises a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 1 1 7, or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VL-region; or

a variable VL-region having an amino acid sequence as shown in SEQ ID NO:89, or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region.

21 . The antibody of claim 1 6,

wherein said antibody comprises a variable VH-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 122, or a variable VH-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VH-region; or

a variable VH-region having an amino acid sequence as shown in SEQ ID NO:106, or a variable VH-region having an amino acid sequence which has 75% or more identity to said variable VH-region; and

wherein said antibody comprises a variable VL-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 121 , or a variable VL-region as encoded by a nucleic acid molecule having 75% or more identity to said variable VL-region; or

a variable VL-region having an amino acid sequence as shown in SEQ ID NO: 105, or a variable VL-region having an amino acid sequence which has 75% or more identity to said variable VL-region .

22. The antibody of any one of claims 1-21 , wherein said antibody binds to a protein having SEQ ID NO:1 , SEQ ID NO:2, or SEQ ID NO:3.

23. The antibody of any one of claims 1-21 , wherein said antibody binds to an epitope having an amino acid sequence as in one of SEQ ID NOs: 4-16.

24. An antibody that blocks or inhibits the binding of an antibody of anyone of claims 1 -21 to CADM1 or a protein having SEQ ID NO: 1 , SEQ ID NO:2, or SEQ ID NO:3.

25. An antibody that specifically binds to CADM1 , wherein said antibody binds to an epitope on CADM1 recognized by the antibody of any of claims 1 to 21 .

26. The antibody of any one of claims 1 to 25, wherein said antibody is selected from the group consisting of a full antibody (immunoglobulin), an antibody fragment such as a F(ab)-fragment or a F(ab)2-fragment, a single-chain antibody, a chimeric antibody, a humanized antibody, a human antibody, a fully human antibody, a CDR-grafted antibody, a bivalent antibody-construct, a bispecific single-chain antibody, a synthetic antibody and a cross-cloned antibody.

27. The antibody of claim 26 wherein said antibody is an immunoglobulin selected from the group consisting of IgA, IgD, IgE, IgG or IgM antibody.

28. The antibody of one of claims 1-21 , wherein said antibody is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, and a fully human antibody.

29. An antibody of any one of claims 1 -21 in a human antibody framework.

30. The antibody of any one of claims 1-29, wherein said antibody is an antibody conjugated to a toxin and/or therapeutic agent.

31 . The antibody of one of claims 1 -21 wherein said antibody is a diagnostic antibody.

32. The antibody of claim 31 having a detectable label.

33. The antibody of any one of claims 1 -30 wherein said antibody modulates cell adhesion.

34. The antibody of any one of claims 1 -30 wherein said antibody modulates cell migration.

35. An antibody as in one of claims 1-30 wherein said antibody is capable of internalizing when bound to a CADM1.

36. A nucleic acid, or the complement thereof, encoding an antibody as in any of claims 1 -30.

37. A vector comprising the nucleic acid of claim 36.

38. A host cell comprising a nucleic acid of claim 36 or the vector of claim 37.

39. The host cell of claim 38 wherein said host cell is capable of producing an antibody of one of claims 1 -30.

40. The host cell of claim 39 which is a prokaryotic or eukaryotic host cell.

41 . The host cell of claim 40 which is a eukaryotic host cell chosen from COS, CHO, HEK293 or a multiple myeloma host cell.

42. A process for the production of the antibody as defined in any one of claims 1 to 30, said process comprising culturing a host of claim 38 to 41 under conditions allowing the expression of the antibody and recovering the produced antibody from the culture.

43. A pharmaceutical composition comprising the antibody of any one of claims 1 -30 and a pharmaceutically acceptable carrier.

44. The antibody of any one of claims 1 to 30 or as produced by the process of claim 42, and/or the composition of claim 43 for use in medicine.

45. The antibody of any one of claims 1 to 30 or as produced by the process of claim 42, and/or the composition of claim 43 for use in the treatment of cancer.

46. Use of the antibody of any one of claims 1 to 30 or as produced by the process of claim 42 for the preparation of a pharmaceutical composition for the treatment of cancer.

47. A method of treating an individual having cancer comprising administering to said individual a therapeutically effective amount of a therapeutic antibody to CADM1 wherein said antibody is as in any one of claims 1 -30.

48. The method of claim 47, wherein said therapeutic antibody is administered in a successive, sequential or simultaneous treatment regimen, and is administered intravenously or intraperitoneally to said individual.

49. The method of claim 47 or 48, wherein said individual is a human.

50. The antibody of claim 45, the use of claim 46 or the method of claim 47 to 49, wherein said cancer is melanoma, colon and/or colorectal cancer or prostate cancer.

51 . The antibody of claim 50, the use of claim 50 or the method of claim 50, wherein said cancer is melanoma.

52. The antibody of claim 50, the use of claim 50 or the method of claim 50, wherein said cancer is colon and/or colorectal cancer.

53. The antibody of claim 50, the use of claim 50 or the method of claim 50, wherein said cancer is prostate cancer.

54. A method of diagnosing prostate cancer comprising:

obtaining or providing a sample from an individual and determining the protein level of CADM1 in the sample wherein increased levels of CADM1 in the sample indicate prostate cancer or an increased likelihood of prostate cancer, wherein the protein level of CADM1 is determined using an antibody of any one of claims 1 to 21 .

55. The method of claim 54 wherein said sample is a serum, blood, or plasma sample.

56 A method of treating an individual having cancer comprising administering to said individual a therapeutically effective amount of the antibody of claim 28 or 29.

57. The method of claim 56 wherein said cancer is melanoma, colorectal, prostate, kidney, lung, ovarian, breast, blood or pancreatic cancer.

58. The method of claim 57 wherein said cancer is melanoma.

59. The method of claim 57 wherein said cancer is colorectal cancer.

60. The method of claim 57 wherein said cancer is prostate cancer.

61 . The method of any one of claims 56-60 wherein said antibody reduces levels of activity of CADM1.

62. The method of any one of claims 56-60 wherein said antibody inhibits or reduces proliferation; causes cytotoxicity; inhibits or reduces metastasis; modulates, inhibits or reduces cell adhesion; modulates, inhibits or reduces migration; or modulates, inhibits or reduces invasion of cancer cells, cancer, prostate cancer or prostate cancer cells expressing CADM1 .

63. The method of any one of claims 56-60 wherein said antibody inhibits or reduces proliferation of prostate cancer, prostate cancer cells, cancer, or cancer cells expressing CADM1 .

64. The method of any one of claims 56-60 wherein said antibody causes cytotoxicity to prostate cancer, prostate cancer cells, cancer, or cancer cells expressing CADM1 .

65. The method of any one of claims 56-60 wherein said antibody reduces or inhibits metastasis of prostate cancer, prostate cancer cells, cancer, or cancer cells expressing CADM1 .

66. The method of any one of claims 56-60 wherein said antibody reduces or inhibits cell adhesion of prostate cancer, prostate cancer cells, cancer or cancer cells expressing CADM1 .

67. The method of any one of claims 56-60 wherein said antibody reduces or inhibits invasion of prostate cancer, prostate cancer cells, cancer or cancer cells expressing CADM1 .

68. The method of any one of claims 56-60 wherein said antibody reduces or inhibits migration of prostate cancer, prostate cancer cells, cancer or cancer cells expressing CADM1 .

69. The method of any one of claims 56-60 wherein said antibody induces, enhances, or mediates ADCC (antibody dependent cellular cytotoxicity) against cells to which it binds.

70. The method of any one of claims 56-60 wherein said antibody to CADM1 induces, enhances, or mediates CDC (complement dependent cytotoxicity) against cells to which it binds.

71 . The method of any one of claims 56-60 wherein said antibody is conjugated to another molecule.

72. The method of any one of claims 56-60 wherein said antibody is conjugated to a cytotoxin, a radioactive agent, enzyme, toxin, an anti-tumor drug or a therapeutic agent.